In the third quarter, Dyne beat expectations with a loss of $0.76 per share versus the $0.84 consensus estimate. Late last year, the company presented positive topline results for the DELIVER trial in ...
Chugai Pharma introduces “Elevidys” as Japan’s first regenerative medical product for Duchenne muscular dystrophy: Tokyo Monday, February 23, 2026, 11:00 Hrs [IST] Chugai Ph ...
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted ...
The Well News on MSNOpinion
Despite lofty rhetoric, FDA still failing patients and taxpayers
Hope abounds that, after years of rejecting lifesaving medications, the Food and Drug Administration is turning things around ...
Sarepta Therapeutics and partner Roche have reported a second case of fatal liver failure with their Duchenne muscular dystrophy (DMD) gene therapy Elevidys and stopped using it to treat some patients ...
The FDA has launched a formal investigation into two reports of fatal acute liver failure in patients treated with Sarepta and Roche's Duchenne muscular dystrophy (DMD) gene therapy Elevidys. The two ...
– U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical study in patients with Duchenne muscular dystrophy (DMD) – – ...
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy – U.S. FDA Study May Proceed ...
Suzuki Access 125 gets a 4.2-inch TFT digital display with smartphone connectivity via its Ride Connect tech. Besides, the model gets all LED lighting, a USB port, and the newly-launched version has ...
Duchenne muscular dystrophy (DMD) is the most common and one of the most severe types of muscular dystrophy. Symptoms usually start between ages 2 and 6, and muscle weakness worsens quickly. DMD ...
The Suzuki Access 125 has long been one of those scooters that quietly gets everything right. It doesn’t shout about being sporty or ultra-premium, yet year after year it remains a top pick for ...
After our formal remarks, we will open the call for Q&A. I would like to note that during this call, we will be making a number of forward-looking statements. Please refer to Slide 2 on the webcast, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results